upadacitinib


( Last Updated : June 28, 2021)
Generic Name:
upadacitinib
Project Status:
Active
Therapeutic Area:
Psoriatic Arthritis, Adults.
Manufacturer:
AbbVie
Brand Name:
Rinvoq
Project Line:
Reimbursement Review
Project Number:
SR0658-000

Details


Manufacturer Requested Reimbursement Criteria1:
Indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to, one or more DMARDs. Rinvoq may be used as monotherapy or in combination with nonbiologic DMARDs.
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
Rinvoq is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to, one or more DMARDs. Rinvoq may be used as monotherapy or in combination with nonbiologic DMARDs.
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient/clinician input openNovember 27, 2020
Call for patient/clinician input closedJanuary 29, 2021
Clarification:

- Patient input submission received from Arthritis Consumer Experts, Canadian Arthritis Patient Alliance and Arthritis Society, Canadian Association of Psoriasis Patients and Canadian Psoriasis Network, Canadian Spondylitis Association

Submission receivedJanuary 04, 2021
Submission acceptedJanuary 18, 2021
Review initiatedJanuary 19, 2021
Draft CADTH review report(s) provided to sponsor for commentApril 19, 2021
Deadline for sponsors commentsApril 28, 2021
CADTH responses on draft review report(s) provided to sponsorJune 04, 2021
Expert committee meeting (initial)June 16, 2021
Draft recommendation issued to sponsorJune 28, 2021
Draft recommendation posted for stakeholder feedbackJuly 08, 2021
End of feedback periodJuly 22, 2021
Final recommendation issued to sponsor and drug plansAugust 04, 2021
Final recommendation posted
Deadline for sponsor to submit redaction requests on draft CADTH review report(s)
CADTH review report(s) posted